Russell Investments Group
IOVA icon

Russell Investments Group’s Iovance Biotherapeutics IOVA Stock Holding History

Russell Investments Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
193,053
+29,961
+18% +$114K ﹤0.01% 2571
2026
Q1 		$572K Sell
163,092
-34,951
-18% -$112K ﹤0.01% 2448
2025
Q4 		$541K Buy
198,043
+131,072
+196% +$303K ﹤0.01% 2465
2025
Q3 		$145K Buy
66,971
+26,624
+66% +$62.9K ﹤0.01% 2913
2025
Q2 		$69.4K Buy
40,347
+31,807
+372% +$79.1K ﹤0.01% 2908
2025
Q1 		$28.4K Buy
8,540
+1,862
+28% +$9.6K ﹤0.01% 3033
2024
Q4 		$49.4K Sell
6,678
-590
-8% -$5.47K ﹤0.01% 2830
2024
Q3 		$68.2K Sell
7,268
-14,732
-67% -$140K ﹤0.01% 2727
2024
Q2 		$176K Buy
22,000
+21,165
+2,535% +$227K ﹤0.01% 2511
2024
Q1 		$12.4K Sell
835
-7,200
-90% -$83.8K ﹤0.01% 2825
2023
Q4 		$65.3K Sell
8,035
-5,285
-40% -$27.7K ﹤0.01% 2609
2023
Q3 		$60.6K Sell
13,320
-11,779
-47% -$76.9K ﹤0.01% 2721
2023
Q2 		$177K Sell
25,099
-141,499
-85% -$1.01M ﹤0.01% 2493
2023
Q1 		$1.02M Buy
166,598
+121,440
+269% +$838K ﹤0.01% 1955
2022
Q4 		$289K Buy
45,158
+25,751
+133% +$201K ﹤0.01% 2475
2022
Q3 		$184K Sell
19,407
-6,457
-25% -$74.5K ﹤0.01% 2561
2022
Q2 		$284K Buy
25,864
+25,029
+2,997% +$328K ﹤0.01% 2457
2022
Q1 		$13K Buy
+835
New +$12.9K ﹤0.01% 2699
2021
Q3 		– Sell
-11,073
Closed -$287K – 3124
2021
Q2 		$287K Sell
11,073
-10,291
-48% -$267K ﹤0.01% 2794
2021
Q1 		$675K Buy
21,364
+10,420
+95% +$432K ﹤0.01% 2397
2020
Q4 		$507K Hold
10,944
– – ﹤0.01% 2422
2020
Q3 		$360K Sell
10,944
-50,630
-82% -$1.55M ﹤0.01% 2540
2020
Q2 		$1.69M Sell
61,574
-23,115
-27% -$760K ﹤0.01% 1739
2020
Q1 		$2.53M Sell
84,689
-183
-0.2% -$4.85K 0.01% 1341
2019
Q4 		$2.35M Buy
84,872
+36,520
+76% +$831K ﹤0.01% 1642
2019
Q3 		$880K Buy
+48,352
New +$1.07M ﹤0.01% 2059
2017
Q4 		– Sell
-16,732
Closed -$130K – 2978
2017
Q3 		$130K Sell
16,732
-35,029
-68% -$222K ﹤0.01% 2740
2017
Q2 		$380K Hold
51,761
– – ﹤0.01% 2522
2017
Q1 		$386K Buy
+51,761
New +$379K ﹤0.01% 2517

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Russell Investments Group's IOVA Position: Q2 2026 in Review

Russell Investments Group increased its Iovance Biotherapeutics (IOVA) stake by 18% in Q2 2026, buying an estimated $114K and bringing the position to 193,053 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Russell Investments Group first reported a position in IOVA in Q1 2017 and has held it in 29 quarters since. The position peaked at $2.53M in Q1 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Russell Investments Group held 193,053 shares of Iovance Biotherapeutics worth $803K as of Q2 2026.
  • Russell Investments Group bought 29,961 Iovance Biotherapeutics shares in Q2 2026, an estimated $114K.
  • Iovance Biotherapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2571 holding.
  • Russell Investments Group first reported a position in Iovance Biotherapeutics in Q1 2017 and has held it in 29 quarters since.
  • Russell Investments Group's Iovance Biotherapeutics position peaked at $2.53M in Q1 2020.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.